Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics IncfiledCriticalPharmacyclics Inc
Priority claimed from PCT/US2011/039190external-prioritypatent/WO2011153514A2/en
Publication of UA107707C2publicationCriticalpatent/UA107707C2/en
Пропонується застосування сполуки, яка має структуру:,у кількості від 420 мг/день до 840 мг/день, включно, для лікування рецидивної або рефрактерної неходжкінської лімфоми у індивіда.It is proposed to use a compound having the structure: in an amount of from 420 mg / day to 840 mg / day, inclusive, for the treatment of recurrent or refractory non-Hodgkin's lymphoma in an individual.
UAA201214953A2010-06-032011-03-06The use of inhibitors of bruton's tyrosine kinase (btk)
UA107707C2
(en)
Compounds derived from 5-phenyl-1h-pyridin-2-one and 5-phenyl-pyrazin-2-one, bruton tyrosine kinase inhibitors (btk); process of preparation of the compounds, intermediate compound, pharmaceutical composition and use in the treatment of inflammatory and / or autoimmune diseases.